Frost & Sullivan Independent Equity Research
Entera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.
Company: DNA Biomedical Solutions Ltd.
Report type: Immediate Update
Published on: 1 July, 2018